Ricardo A. Santos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ricardo A. Santos has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Ada Gabriela Blidner
Laboratory of Immunopathology, Institute of Biology and Experimental Medicine-CONICET, Buenos Aires, Argentina
13 shared publications - Alessandro Fatatis
Department of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, USA
13 shared publications - Camila A. Bach
Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, Pennsylvania
13 shared publications - Candice L. Bizzaro
Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, Pennsylvania
13 shared publications - Cecilia E. Verrillo
Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, Pennsylvania
13 shared publications - David W. Goodrich
Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York
13 shared publications
Latest Publications
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S5 from Exploring STEAP1 Expression in Prostate Cancer Cells in Response to Androgen Deprivation and in Small Extracellular Vesicles
Particle size distributions obtained by Zeta View of sEVs derived from WT and TR mouse plasma (A-B) Zetaview Nanoparticle tracking analysis measurement of size distribution and concentration of iodixanol density gradient isolated md-sEVs derived from (A) WT or (B) TR mouse plasma.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S5 from Exploring STEAP1 Expression in Prostate Cancer Cells in Response to Androgen Deprivation and in Small Extracellular Vesicles
Particle size distributions obtained by Zeta View of sEVs derived from WT and TR mouse plasma (A-B) Zetaview Nanoparticle tracking analysis measurement of size distribution and concentration of iodixanol density gradient isolated md-sEVs derived from (A) WT or (B) TR mouse plasma.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table S1 from Exploring STEAP1 Expression in Prostate Cancer Cells in Response to Androgen Deprivation and in Small Extracellular Vesicles
Supplemental Table S1: Description of PCa mouse model genetic backgrounds and their circulating sEVs
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S1 from Exploring STEAP1 Expression in Prostate Cancer Cells in Response to Androgen Deprivation and in Small Extracellular Vesicles
Supplemental Table S1: Description of PCa mouse model genetic backgrounds and their circulating sEVs
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S3 from Exploring STEAP1 Expression in Prostate Cancer Cells in Response to Androgen Deprivation and in Small Extracellular Vesicles
Correlation of STEAP1 expression with AR and AR target genes in primary and metastatic PCa cohorts Gene expression correlations of STEAP1, AR and canonical AR target genes KLK2, KLK3, KLK15, NKX3-1 and TMPRSS2. mRNA expression from Z-scores quantified by RNA Seq V2 RSEM for primary and FPKM for metastatic. (A) Primary Prostate Adenocarcinoma (TCGA Firehose Legacy) and (B) Metastatic Prostate Adenocarcinoma (SU2C/PCF Dream Team, 2019). (C) RNA-sequencing values from 210 mCRPC patient biopsies. Correlations between Z-scores of AR activity (top row) and KLK3 (bottom row) with STEAP1 and STEAP2. AR activity was measured as the mean Z-score of 7 AR target genes.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S3 from Exploring STEAP1 Expression in Prostate Cancer Cells in Response to Androgen Deprivation and in Small Extracellular Vesicles
Correlation of STEAP1 expression with AR and AR target genes in primary and metastatic PCa cohorts Gene expression correlations of STEAP1, AR and canonical AR target genes KLK2, KLK3, KLK15, NKX3-1 and TMPRSS2. mRNA expression from Z-scores quantified by RNA Seq V2 RSEM for primary and FPKM for metastatic. (A) Primary Prostate Adenocarcinoma (TCGA Firehose Legacy) and (B) Metastatic Prostate Adenocarcinoma (SU2C/PCF Dream Team, 2019). (C) RNA-sequencing values from 210 mCRPC patient biopsies. Correlations between Z-scores of AR activity (top row) and KLK3 (bottom row) with STEAP1 and STEAP2. AR activity was measured as the mean Z-score of 7 AR target genes.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S2 from Exploring STEAP1 Expression in Prostate Cancer Cells in Response to Androgen Deprivation and in Small Extracellular Vesicles
STEAP expression changes with DHT dose response Relative mRNA expression of (A) STEAP2 and STEAP4 in LNCaP cells and (B) STEAP1, STEAP2, STEAP4 and KLK3 expression in C42 cells treated with 0 nM (DMSO), 0.1 nM, 1 nM, and 10 nM DHT for 24 hours in regular growth or CSS conditions. P-values were calculated using two-way ANOVA followed by post-hoc Tukey test for multiple comparisons.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S2 from Exploring STEAP1 Expression in Prostate Cancer Cells in Response to Androgen Deprivation and in Small Extracellular Vesicles
STEAP expression changes with DHT dose response Relative mRNA expression of (A) STEAP2 and STEAP4 in LNCaP cells and (B) STEAP1, STEAP2, STEAP4 and KLK3 expression in C42 cells treated with 0 nM (DMSO), 0.1 nM, 1 nM, and 10 nM DHT for 24 hours in regular growth or CSS conditions. P-values were calculated using two-way ANOVA followed by post-hoc Tukey test for multiple comparisons.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S6 from Exploring STEAP1 Expression in Prostate Cancer Cells in Response to Androgen Deprivation and in Small Extracellular Vesicles
Particle size distributions obtained by Nanoparticle tracking analysis (NTA) of sEVs derived from β1 FF or β1 FF TR mouse plasma (A-B) NTA measurement of size distribution and concentration of iodixanol density gradient isolated md-sEVs derived from (A) β1 FF or (B) β1 FF TR mouse plasma.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S6 from Exploring STEAP1 Expression in Prostate Cancer Cells in Response to Androgen Deprivation and in Small Extracellular Vesicles
Particle size distributions obtained by Nanoparticle tracking analysis (NTA) of sEVs derived from β1 FF or β1 FF TR mouse plasma (A-B) NTA measurement of size distribution and concentration of iodixanol density gradient isolated md-sEVs derived from (A) β1 FF or (B) β1 FF TR mouse plasma.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table S3 from Exploring STEAP1 Expression in Prostate Cancer Cells in Response to Androgen Deprivation and in Small Extracellular Vesicles
Supplemental Table S3: SMARTpool STEAP1 targeting siRNA Primer Sequences
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S3 from Exploring STEAP1 Expression in Prostate Cancer Cells in Response to Androgen Deprivation and in Small Extracellular Vesicles
Supplemental Table S3: SMARTpool STEAP1 targeting siRNA Primer Sequences
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table S4 from Exploring STEAP1 Expression in Prostate Cancer Cells in Response to Androgen Deprivation and in Small Extracellular Vesicles
Supplemental Table S4: Immunoblotting of human PCa cells and derived sEVs Summary
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S4 from Exploring STEAP1 Expression in Prostate Cancer Cells in Response to Androgen Deprivation and in Small Extracellular Vesicles
Supplemental Table S4: Immunoblotting of human PCa cells and derived sEVs Summary
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S1 from Exploring STEAP1 Expression in Prostate Cancer Cells in Response to Androgen Deprivation and in Small Extracellular Vesicles
STEAP mRNA expression in response to AR antagonist Relative mRNA expression of STEAP1, STEAP2, STEAP4 and KLK3 in (A) LNCaP cells, (B) C4-2 cells and (C) 22Rv1 cells treated with indicated doses of enzalutamide for 24 hours in regular growth or CSS conditions. KLK3 is the positive control for AR signaling response. Experiments were performed in n = 3 or n = 4. The values are presented as replicates with error bars representing mean ± SEM. P-values were calculated using Two-Way ANOVA with a 95% confidence interval threshold followed by post-hoc Dunnett test for multiple comparisons.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S1 from Exploring STEAP1 Expression in Prostate Cancer Cells in Response to Androgen Deprivation and in Small Extracellular Vesicles
STEAP mRNA expression in response to AR antagonist Relative mRNA expression of STEAP1, STEAP2, STEAP4 and KLK3 in (A) LNCaP cells, (B) C4-2 cells and (C) 22Rv1 cells treated with indicated doses of enzalutamide for 24 hours in regular growth or CSS conditions. KLK3 is the positive control for AR signaling response. Experiments were performed in n = 3 or n = 4. The values are presented as replicates with error bars representing mean ± SEM. P-values were calculated using Two-Way ANOVA with a 95% confidence interval threshold followed by post-hoc Dunnett test for multiple comparisons.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table S5 from Exploring STEAP1 Expression in Prostate Cancer Cells in Response to Androgen Deprivation and in Small Extracellular Vesicles
Supplemental Table S5: Immunoblotting results of mouse PCa derived sEVs
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S5 from Exploring STEAP1 Expression in Prostate Cancer Cells in Response to Androgen Deprivation and in Small Extracellular Vesicles
Supplemental Table S5: Immunoblotting results of mouse PCa derived sEVs
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Data from Exploring STEAP1 Expression in Prostate Cancer Cells in Response to Androgen Deprivation and in Small Extracellular Vesicles
The six-transmembrane epithelial antigen of the prostate (STEAP; STEAP1 and STEAP2) metalloreductases are therapeutic targets for advanced prostate cancer, and their expression has been linked to androgen receptor (AR) signaling; however, the regulatory mechanism and functions of STEAP1 and STEAP2 in prostate cancer progression remain elusive. In this study, we explore how in vitro androgen modulation and AR inhibition influence the expression of STEAP family members in cell lines with varying reliance on androgen signaling. Our data show that in response to androgen deprivation, STEAP1 and STEAP2 exhibit elevated transcript levels, whereas STEAP4 levels are reduced, mirroring the expression profile of kallikrein-related peptidase 3 (KLK3). As STEAP1 and STEAP2 are implicated in the exocytic pathway, we evaluated expression profiles in small extracellular vesicles (sEV) released from prostate cancer cells and in circulating sEVs. STEAP1, but not STEAP2, is upregulated in sEVs from AR-negative cells, which express low cellular STEAP1, and AR-positive cells, which express high cellular STEAP1. These results indicate selective packaging of STEAP1 in prostate cancer cell–derived sEVs, irrespective of AR status and cellular STEAP1 expression levels. Finally, ex vivo analysis of circulating sEVs from genetically engineered mice carrying prostate cancer shows that STEAP1 is found in the sEV cargo and that its levels are independent of protumorigenic β1 integrin expression in the prostatic epithelium.Implications:Understanding how androgen dependence affects STEAP1 expression in both tumor cells and sEVs across distinct disease stages will illuminate the clinical benefit of combinatorial AR and STEAP1-directed therapies and inform the optimal placement of STEAP1 targeting within the prostate cancer disease continuum.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Exploring STEAP1 Expression in Prostate Cancer Cells in Response to Androgen Deprivation and in Small Extracellular Vesicles
The six-transmembrane epithelial antigen of the prostate (STEAP; STEAP1 and STEAP2) metalloreductases are therapeutic targets for advanced prostate cancer, and their expression has been linked to androgen receptor (AR) signaling; however, the regulatory mechanism and functions of STEAP1 and STEAP2 in prostate cancer progression remain elusive. In this study, we explore how in vitro androgen modulation and AR inhibition influence the expression of STEAP family members in cell lines with varying reliance on androgen signaling. Our data show that in response to androgen deprivation, STEAP1 and STEAP2 exhibit elevated transcript levels, whereas STEAP4 levels are reduced, mirroring the expression profile of kallikrein-related peptidase 3 (KLK3). As STEAP1 and STEAP2 are implicated in the exocytic pathway, we evaluated expression profiles in small extracellular vesicles (sEV) released from prostate cancer cells and in circulating sEVs. STEAP1, but not STEAP2, is upregulated in sEVs from AR-negative cells, which express low cellular STEAP1, and AR-positive cells, which express high cellular STEAP1. These results indicate selective packaging of STEAP1 in prostate cancer cell–derived sEVs, irrespective of AR status and cellular STEAP1 expression levels. Finally, ex vivo analysis of circulating sEVs from genetically engineered mice carrying prostate cancer shows that STEAP1 is found in the sEV cargo and that its levels are independent of protumorigenic β1 integrin expression in the prostatic epithelium.Implications:Understanding how androgen dependence affects STEAP1 expression in both tumor cells and sEVs across distinct disease stages will illuminate the clinical benefit of combinatorial AR and STEAP1-directed therapies and inform the optimal placement of STEAP1 targeting within the prostate cancer disease continuum.